Avian influenza A(H7N9) is a novel reassortant avian-origin influenza virus that emerged in China in 2013, causing 1,568 confirmed human infections with a case-fatality ratio of ~40%. [1] No new human cases have been detected since 2019, but H7N9 remains ranked by the CDC as the influenza virus with the highest potential pandemic risk. [2] The vast majority of cases result from poultry exposure (especially live bird markets), with no sustained human-to-human transmission documented. [3]
1. History
- Exposure history is paramount: Ask about contact with live poultry, visits to live bird markets, occupational poultry work, or travel to endemic areas (mainland China) within the prior 10 days [4-5]
- Incubation period: 3–8 days (mean ~5–6 days) [6]
- Symptom onset: High fever (often ≥39°C), cough (initially dry, then productive), dyspnea, sputum production [7-8]
- Timing/progression: Rapid deterioration — median onset-to-hospitalization 4 days, onset-to-ARDS 7 days, onset-to-death 21 days [3]
- Associated symptoms: Myalgia, hemoptysis (in ~24%), chest tightness/distress, diarrhea or vomiting (~13.5%) [7-8]
- Important negatives: Upper respiratory tract symptoms (rhinorrhea, sore throat) and conjunctivitis are typically absent, distinguishing H7N9 from other H7 subtypes and seasonal influenza [6]
2. Alarm Features
- Rapidly progressive dyspnea with hypoxemia (mean onset-to-respiratory failure ~9 days) [6]
- Bilateral ground-glass opacities on imaging with rapid multilobar progression [7][9]
- Hemoptysis [8]
- Septic shock, multiorgan dysfunction (renal failure, rhabdomyolysis, DIC) [10-11]
- Refractory hypoxemia not responding to standard antibiotics — a hallmark clue to novel viral pneumonia [6]
- ARDS developed in the majority of hospitalized patients (83–90%) [3][11]
3. Medications
- Neuraminidase inhibitors (NAIs) are the cornerstone of treatment: [12-13]
- Oseltamivir 75 mg PO BID × 5 days (standard); higher doses (150 mg BID) have been used in critically ill patients [7][14]
- Peramivir 600 mg IV daily — useful when oral route is unavailable [8][15]
- Zanamivir (inhaled or IV where available) is an alternative [12]
- Initiate antivirals empirically based on clinical suspicion; do not wait for confirmatory testing [13]
- Early treatment (within 48 hours) is associated with lower mortality, but benefit may extend up to 5 days post-onset [3-4]
- Contraindicated/avoid:
- Adamantanes (amantadine, rimantadine) — H7N9 viruses are universally resistant [3]
- Corticosteroids — should be avoided; associated with prolonged viral shedding and worse outcomes [13]
- Salicylates — avoid due to Reye syndrome risk [13]
- Resistance concern: R292K neuraminidase mutation conferring NAI resistance has emerged during oseltamivir treatment in critically ill patients [2-3]
4. Diet
- Food safety: Avoid undercooked or raw poultry/eggs and foods containing animal blood in endemic areas [1]
- Hydration: Aggressive IV fluid resuscitation as needed for sepsis/shock, balanced against ARDS fluid management (conservative strategy once stabilized)
- No specific dietary triggers or long-term dietary management applicable
5. Review of Systems
- Respiratory: Cough, dyspnea, sputum production, hemoptysis, chest tightness
- Constitutional: Fever (universal), chills, fatigue, myalgia
- GI: Diarrhea, vomiting (~13.5%) [7]
- Neuropsychiatric: Altered mental status, neuropsychiatric symptoms reported in ~33% of one series [11]
- Renal: Decreased urine output (acute kidney injury)
- Musculoskeletal: Myalgia, rhabdomyolysis (elevated CK) [6][11]
6. Collateral History and Family History
- Collateral: Determine household poultry exposure, sick contacts with similar illness, recent travel to China or areas with known H7N9 outbreaks [1]
- Family clusters: Four family clusters were identified where limited human-to-human transmission could not be excluded — ask about ill family members [3]
- Genetic susceptibility: IFITM3 rs12252-C/C genotype may predict severe illness [8]
- Social context: Occupation (poultry worker, market vendor), urban vs. rural residence, proximity to live bird markets [3]
7. Risk Factors
- Poultry exposure: Visiting live poultry markets (adjusted OR 3.4), direct contact with poultry (matched OR 7.8) [5]
- Age: Median age 61 years; patients ≥60 years have significantly higher fatality risk (aOR 1.84 for ages 60–74, 2.28 for ≥75) [4]
- Male sex: Male-to-female ratio 2.4:1 [12]
- Comorbidities: Underlying medical conditions present in 61–73% of cases; coexisting conditions are the only independent risk factor for ARDS (OR 3.42) [3][7]
- Obesity (matched OR 4.7), COPD (matched OR 2.7), immunosuppressive medications (matched OR 9.0) [5]
- Delayed antiviral treatment: Initiation >48 hours after symptom onset associated with higher mortality [4]
8. Differential Diagnosis
- Seasonal influenza A/B — milder course, upper respiratory symptoms more common, responds to standard antibiotics less likely to be needed
- Avian influenza A(H5N1) — similar severity but younger median age (29 years vs. 61), longer onset-to-hospitalization [7]
- SARS-CoV-2 / COVID-19 — overlapping imaging findings; distinguish by exposure history and PCR
- MERS-CoV — travel to Middle East, camel exposure
- Bacterial community-acquired pneumonia (Legionella, Streptococcus pneumoniae) — responds to antibiotics
- Other viral pneumonias: RSV, adenovirus, hantavirus pulmonary syndrome
- Pneumocystis jirovecii pneumonia — in immunocompromised patients with bilateral GGOs
- Key distinguishing feature: Rapidly progressive bilateral pneumonia not responding to antibiotics in a patient with poultry exposure should raise immediate suspicion [6-7]
9. Past Medical History
- Document all chronic medical conditions — hypertension, diabetes, cardiovascular disease, chronic lung disease, chronic kidney disease [3][7]
- Prior episodes of influenza or avian influenza exposure
- Immunosuppressive therapy or conditions (transplant, HIV, malignancy) — significantly increase risk [5]
- Surgical history (relevant for ventilatory management)
- Vaccination history (seasonal influenza vaccine does not protect against H7N9) [14]
10. Physical Exam
- Vital signs: High fever (often >39°C), tachypnea, tachycardia, hypoxemia (SpO₂ often <93% on room air), hypotension in shock [6][10]
- Respiratory: Bilateral crackles/rales, decreased breath sounds, signs of respiratory distress (accessory muscle use, nasal flaring)
- General: Toxic appearance, diaphoresis
- Notably absent: Upper airway findings (pharyngeal erythema, rhinorrhea), conjunctivitis [6]
- Concerning findings: Cyanosis, altered mental status, signs of multiorgan failure (jaundice, oliguria, petechiae)
11. Lab Studies
- CBC: Lymphocytopenia (88.3%), thrombocytopenia (73.0%), normal or low WBC [7]
- Chemistry: Elevated AST, LDH, creatine kinase (nearly universal) — suggestive of multiorgan involvement and myositis [6-7]
- Inflammatory markers: Elevated CRP, procalcitonin [11]
- Coagulation: Impaired coagulation/DIC markers [6]
- Renal function: Monitor for acute kidney injury [10]
- Cytokine panel (if available): Markedly elevated IL-6, IL-10, and other pro-inflammatory cytokines correlate with severity [6]
- Blood cultures: To rule out bacterial co-infection (Klebsiella, MRSA, Acinetobacter reported) [7][10]
12. Imaging
- First-line: Chest X-ray — 97.3% show pneumonia on admission [7]
- CT chest (preferred for detailed assessment):
- Ground-glass opacities (GGOs) — universal finding [9]
- Consolidation with air bronchograms — multilobar, bilateral [9][16]
- Interlobular septal thickening [9]
- Right lower lobe predominance early, with rapid bilateral spread [16]
- Pleural effusion (~50%), centrilobular nodules, reticular opacities [9][17]
- Follow-up imaging: Shows rapid progression within 1–2 weeks; slow resolution over weeks with residual fibrotic changes (traction bronchiectasis, parenchymal bands) [17]
- Complications on imaging: Pneumomediastinum, pneumothorax, subcutaneous emphysema [17]
13. Special Tests
- Definitive diagnosis: Real-time RT-PCR for H7N9 virus from respiratory specimens (nasopharyngeal aspirate, sputum, tracheal aspirate preferred over NP swab alone) [3][18]
- Standard influenza rapid antigen tests and routine influenza PCR panels will not detect H7N9 — specific H7N9 RT-PCR is required [18]
- Median time from illness onset to negative PCR: 11 days; from antiviral initiation to negative: 6 days [7]
- Viral culture: Confirmatory but slower (35% of cases confirmed this way) [3]
- Serology: Hemagglutinin inhibition assay — useful for retrospective confirmation [3]
- Scoring systems: APACHE II scores have been used for severity assessment [6]
- Notify public health authorities immediately upon clinical suspicion — testing is coordinated through state/CDC laboratories [1]
14. ECG
- Indications: Obtain in all patients given risk of myocarditis, cardiac complications, and hemodynamic instability
- Findings to watch for: Sinus tachycardia, ST-T wave changes (myocarditis), arrhythmias
- Left ventricular failure reported in 33% of one case series [11]
- Monitor for QTc prolongation if using fluoroquinolones or other QT-prolonging antibiotics concurrently
15. Assessment
- H7N9 causes a severe lower respiratory tract illness that rapidly progresses to ARDS and multiorgan failure in the majority of hospitalized patients [7]
- 76.6% of confirmed cases required ICU admission; overall case-fatality ratio ~28–40% [1][7]
- Typical presentation: Elderly male with poultry exposure presenting with high fever, cough, and rapidly progressive bilateral pneumonia unresponsive to antibiotics [6-7]
- Atypical/mild presentations: Reported in children and young adults — mild upper respiratory illness without hospitalization [3][18]
- Complications: ARDS (most common cause of death), secondary bacterial infection (66.7%), septic shock, acute kidney injury, rhabdomyolysis, left ventricular failure, neuropsychiatric symptoms [10-11]
16. Treatment Plan
Initial stabilization
- Immediate airborne + contact + standard precautions (negative pressure room if available) [3][13]
- Supplemental oxygen; early escalation to NIV or mechanical ventilation as needed
- ECMO consideration for refractory hypoxemia [10]
Antiviral therapy
- Oseltamivir 75 mg PO BID (or 150 mg BID in critically ill) — start immediately on clinical suspicion [7][14]
- Peramivir 600 mg IV daily if oral route unavailable [8]
- Duration: Minimum 5 days; extend in critically ill or immunocompromised patients until viral clearance
- CDC recommends twice-daily dosing for oseltamivir prophylaxis of close contacts (not standard once-daily) [1]
Supportive care
- Lung-protective ventilation (low tidal volume 6 mL/kg IBW) for ARDS
- Conservative fluid strategy once hemodynamically stable
- Empiric broad-spectrum antibiotics for suspected bacterial co-infection (fluoroquinolones, piperacillin-tazobactam, carbapenems used in published series) [7]
- Avoid corticosteroids [13]
Public health
- Immediate notification to local/state health department and CDC [1]
- Contact tracing of close contacts with 7-day monitoring [3]
17. Disposition
- Admission criteria: Virtually all confirmed H7N9 cases require hospitalization (99% in published series). Any patient with suspected H7N9 and pneumonia or hypoxemia should be admitted [3]
- ICU admission: Required in ~77% of confirmed cases — low threshold for ICU transfer given rapid deterioration [7]
- Discharge criteria: Clinical improvement, hemodynamic stability, resolving hypoxemia, negative or declining viral load on RT-PCR
- Specialist consultation: Infectious disease (mandatory), pulmonary/critical care, public health authorities [13]
- Observation: Any patient with epidemiologic risk and influenza-like illness without pneumonia should be observed with serial imaging and repeat testing
18. Follow Up / Return Precautions
- Close contacts: Monitor for 7 days for fever or respiratory symptoms; consider post-exposure prophylaxis with oseltamivir (twice-daily dosing per CDC) [1][3]
- Survivors: Follow-up CT shows slow resolution over weeks to months; residual fibrotic changes (traction bronchiectasis, parenchymal bands, cystic lesions) are common [17]
- Return precautions: Seek immediate care for recurrent fever, worsening dyspnea, hemoptysis, altered mental status, or decreased urine output
- Expected recovery: Prolonged — survivors may have significant residual pulmonary fibrosis and functional impairment
- Infection control: Patients should remain in isolation until clinically improved and viral shedding has ceased (confirmed by negative RT-PCR) [3]
References
1. Influenza. — Molly Valleau and Christine M. Szablewski CDC Yellow Book. 2025.
2. Update: Increase in Human Infections With Novel Asian Lineage Avian Influenza A(H7N9) Viruses During the Fifth Epidemic - China, October 1, 2016-August 7, 2017. — Kile JC, Ren R, Liu L, et al. MMWR. Morbidity and Mortality Weekly Report. 2017.
3. Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in China. — Li Q, Zhou L, Zhou M, et al. The New England Journal of Medicine. 2014.
4. Epidemiology of Avian Influenza a H7N9 Virus in Human Beings Across Five Epidemics in Mainland China, 2013-17: An Epidemiological Study of Laboratory-Confirmed Case Series. — Wang X, Jiang H, Wu P, et al. The Lancet. Infectious Diseases. 2017.
5. Risk Factors for Influenza A(H7N9) Disease--China, 2013. — Liu B, Havers F, Chen E, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
6. Human Infections With the Emerging Avian Influenza a H7N9 Virus From Wet Market Poultry: Clinical Analysis and Characterisation of Viral Genome. — Chen Y, Liang W, Yang S, et al. Lancet. 2013.
7. Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection. — Gao HN, Lu HZ, Cao B, et al. The New England Journal of Medicine. 2013.
8. Characteristics of H7N9 Avian Influenza Pneumonia: A Retrospective Analysis of 17 Cases. — Yu WQ, Ji NF, Ding MD, et al. Internal Medicine Journal. 2020.
9. Emerging H7N9 Influenza a (Novel Reassortant Avian-Origin) Pneumonia: Radiologic Findings. — Wang Q, Zhang Z, Shi Y, Jiang Y. Radiology. 2013.
10. Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. — Gao R, Cao B, Hu Y, et al. The New England Journal of Medicine. 2013.
11. A Detailed Epidemiological and Clinical Description of 6 Human Cases of Avian-Origin Influenza a (H7N9) Virus Infection in Shanghai. — Shi J, Xie J, He Z, et al. PloS One. 2013.
12. An Overview of the Characteristics of the Novel Avian Influenza a H7N9 Virus in Humans. — Tan KX, Jacob SA, Chan KG, Lee LH. Frontiers in Microbiology. 2015.
13. Novel Avian Influenza a Virus Infections of Humans. — Uyeki TM, Peiris M. Infectious Disease Clinics of North America. 2019.
14. FDA Drug Label. — Updated date: 2025-04-17. Food and Drug Administration.
15. FDA Orange Book. — FDA Orange Book. 2026.
16. Chest X-Ray and CT Findings of Early H7N9 Avian Influenza Cases. — Lin ZQ, Xu XQ, Zhang KB, et al. Acta Radiologica. 2015.
17. Human Infection With a Novel Avian-Origin Influenza a (H7N9) Virus: Serial Chest Radiographic and CT Findings. — Dai J, Zhou X, Dong D, et al. Chinese Medical Journal. 2014.
18. Viral Lung Infections: Epidemiology, Virology, Clinical Features, and Management of Avian Influenza A(H7N9). — To KK, Chan JF, Yuen KY. Current Opinion in Pulmonary Medicine. 2014.